UNSPSC 85813813: Introduction of monoclonal antibody into bones, percutaneous approach

This classification denotes the group of activities that yields a administrative intervention or procedure to introduction of monoclonal antibody into bones, percutaneous approach. This administrative intervention or procedure is listed in the World Health Organization's International Statistical Classification of Diseases and Related Health Problems or ICD-10 as code 3E0V30M

UNSPSC 85813813, Introduction of monoclonal antibody into bones, percutaneous approach, is a Commodity code that shows no relevant recent state and local procurement activity. The recent opportunities posted under this code reflect clinical services delivery across behavioral health, addiction treatment, emergency medical services, occupational health, wellness programming, and hospital operations—none of which align with the pharmaceutical or interventional medical procedure scope the code nominally describes. State and local jurisdictions are instead using this code tag for general healthcare service procurement spanning emergency medical staffing, urgent care telehealth, nursing home operations, substance use disorder treatment, employee health clinics, and multi-disciplinary behavioral health and social services.

The issuing bodies span counties (DeKalb, Santa Clara, Forsyth, Seminole, Ventura, San Mateo, Brevard, Boulder, Jackson, Rockland, Cobb), cities (Phoenix, Ocala, Atlanta, Chicago), state departments (Texas HHS, Colorado Department of Human Services, Nevada Health Authority, Illinois Secretary of State, New Jersey Department of Health), health authorities and regional cooperative purchasing programs (Inland Empire Health Plan, Sourcewell), and special-purpose districts (school districts, transit authorities). Geographic activity appears concentrated in California, Georgia, Colorado, Nevada, Texas, Florida, Kansas, and regional consortiums serving multiple states, though the code tag appears to be a persistent classification error rather than a signal of actual monoclonal antibody procurement. Business development professionals should treat this code as a watch-list item only; the mismatch between code definition and solicited work suggests either systematic catalog miscoding or a transition in how the issuing bodies classify health services delivery. No direct opportunities for pharmaceutical manufacture, injectable biologics development, or orthopedic intervention supply are visible under this code in current state and local posting activity.